Dare Bioscience, Inc.: financing cash flow
Financing cash flow for Dare Bioscience, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Dare Bioscience, Inc. financial histories
What this measure means
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
Exact concept: us-gaap:NetCashProvidedByUsedInFinancingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 19,277,144 | USD | 2026-03-26 | 10-K · 0001401914-26-000004 |
| 2024-01-01 | 2024-12-31 | 354,522 | USD | 2026-03-26 | 10-K · 0001401914-26-000004 |
| 2023-01-01 | 2023-12-31 | 15,637,120 | USD | 2025-03-31 | 10-K · 0001401914-25-000012 |
| 2022-01-01 | 2022-12-31 | 1,343,354 | USD | 2024-03-28 | 10-K · 0001401914-24-000016 |
| 2021-01-01 | 2021-12-31 | 75,846,766 | USD | 2023-03-30 | 10-K · 0001401914-23-000013 |
| 2020-01-01 | 2020-12-31 | 25,130,672 | USD | 2022-03-31 | 10-K · 0001401914-22-000032 |
| 2019-01-01 | 2019-12-31 | 5,151,702 | USD | 2021-03-30 | 10-K · 0001401914-21-000041 |
| 2018-01-01 | 2018-12-31 | 10,111,952 | USD | 2020-03-27 | 10-K · 0001401914-20-000042 |
| 2017-01-01 | 2017-12-31 | 155,000 | USD | 2019-04-01 | 10-K · 0001401914-19-000015 |
Related financial histories
- Dare Bioscience, Inc.: total assets
- Dare Bioscience, Inc.: total liabilities
- Dare Bioscience, Inc.: stockholders equity
- Dare Bioscience, Inc.: cash and cash equivalents
- Dare Bioscience, Inc.: net income or loss
- Dare Bioscience, Inc.: operating cash flow
- Dare Bioscience, Inc.: capital expenditure payments
- Dare Bioscience, Inc.: revenue
- Dare Bioscience, Inc.: contract revenue excluding tax
- Dare Bioscience, Inc.: investing cash flow
- Dare Bioscience, Inc.: retained earnings or deficit
- Dare Bioscience, Inc.: basic weighted-average shares
- Dare Bioscience, Inc.: diluted weighted-average shares
- Dare Bioscience, Inc.: basic earnings per share
- Dare Bioscience, Inc.: diluted earnings per share
- Dare Bioscience, Inc.: income tax expense or benefit
- Dare Bioscience, Inc.: net property, plant and equipment
- Dare Bioscience, Inc.: share-based compensation expense
- Dare Bioscience, Inc.: operating income or loss
- Dare Bioscience, Inc.: current assets
- Dare Bioscience, Inc.: interest expense
- Dare Bioscience, Inc.: current liabilities
- Dare Bioscience, Inc.: current accounts payable
- Dare Bioscience, Inc.: goodwill carrying amount
- Dare Bioscience, Inc.: operating expenses
- Dare Bioscience, Inc.: research and development expense
Inspect the source
- Entity
- Dare Bioscience, Inc. / CIK 0001401914
- Captured
- 2026-09-20T08:00:44.110Z
- SEC response SHA-256
1a9e5d436251c8650231f065c4c293fc1bb2b6e8877619128801af21ceea9ac3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001401914.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))